Evidence map›Paper›PMID 23559853›Full record

ArticleMolecular vision2013

Altered protein conformation and lower stability of the dystrophic transforming growth factor beta-induced protein mutants.

Heather L Grothe, Morgan R Little, Phayvanh P Sjogren, Angela A Chang, Elizabeth F Nelson, Ching Yuan

Open access · greenAbstract read
In one paragraph

Article in Molecular vision, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Classic lattice corneal dystrophy: a brief review and summary of treatment modalities.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2024
    Review
  2. Analysis and Interpretation of the Impact of Missense Variants in Cancer.International journal of molecular sciences · 2021
    Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Heather L GrotheDepartment of Ophthalmology and Visual Neurosciences, University of Minnesota Medical School, Minneapolis, MN, USA.
Morgan R Little
Phayvanh P Sjogren
Angela A Chang
Elizabeth F Nelson
Ching Yuan
University of Minnesota · USUniversity of Minnesota Medical Center · US

Funding

Visual TestingP30EY011374 · NEI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI NEWMAN, ERIC A · 1996 to 2019
$8.8M
Smad3 inhibitors for ophthalmic applicationsR21EY019552 · NEI · UNIVERSITY OF MINNESOTA · PI YUAN, CHING · 2009 to 2010
$415k
Treatment of BIGH3-related Corneal Dystrophies with MeptidesR21EY017852 · NEI · UNIVERSITY OF MINNESOTA · PI YUAN, CHING · 2007 to 2008
$370k
NEI NIH HHS P30 EY011374NEI NIH HHS R21 EY017852NEI NIH HHS R21EY017852NEI NIH HHS R21 EY019552NEI NIH HHS R21EY019552
6 · The paper itself

Abstract

purposeTransforming growth factor beta-induced protein (TGFBIp) is a widely expressed extracellular matrix protein that plays roles in cell adhesion and migration, differentiation, apoptosis, bone morphogenesis, and carcinogenesis. Mutations of TGFBIp have been linked to stromal corneal dystrophies, a group of protein conformational diseases characterized by abnormal protein aggregations in the cornea. However, the underlying pathogenic mechanism remains elusive due to a lack of insight into the molecular properties of the disease-causing mutants. In the current study, we applied spectroscopic tools to compare the conformation and protein stability of recombinant wild-type (WT) TGFBIp to two dystrophic mutants, R124C and R555W.

methodsA serum-free expression system was used to produce the recombinant TGFBIp proteins. Fluorescence and far-ultraviolet circular dichroism spectroscopies were used to compare WT and dystrophic mutants under various conditions.

resultsOur results showed that dystrophic mutants were processed differentially by the expressing cells and produced different proteolytic fragment patterns by proteolysis. Intrinsic tryptophan fluorescence studies revealed moderate shifts in the emission maxima and increased quenching by iodide ion of mutant TGFBIp, suggesting a different conformation than WT protein. Denaturation experiments indicated a difference in protein stability between WT and mutant proteins. Under oxidizing conditions, the mutants produced higher 1-anilinonaphthalene-8-sulfonic acid and thioflavin T fluorescence signals than the WT, indicating increased protein unfolding and fibril formation, respectively. Finally, far-ultraviolet circular dichroism spectroscopy revealed that WT TGFBIp undergoes concentration-dependent conformational changes; similar experiments were not possible on mutant TGFBIp, which remained soluble only at low concentrations.

conclusionsOur study provides new evidence for the pathogenic mechanism of dystrophic mutants. Although mutant TGFBIp has moderate but consistent structural perturbations, other factors such as oxidation or degradation may be required to cause the phenotypic abnormal aggregations.

Indexed as

Anilino NaphthalenesulfonatesBenzothiazolesbetaIG-H3 ProteinCircular DichroismCorneal Dystrophies, HereditaryExtracellular Matrix ProteinsHumansMutant ProteinsProtein ConformationProtein StabilityProteolysisRecombinant ProteinsSpectrometry, FluorescenceThiazolesTransforming Growth Factor betaTryptophan1-anilino-8-naphthalenesulfonateAnilino NaphthalenesulfonatesBenzothiazolesbetaIG-H3 ProteinExtracellular Matrix ProteinsMutant ProteinsRecombinant ProteinsThiazolesthioflavin TTransforming Growth Factor betaTryptophan

Identifiers

PMID23559853
PMCPMC3611947
OpenAlexW2161866238

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.